Drugmakers are pouring billions of dollars toward the advancement of treatments that target cancer more precisely than mainstay treatments like radiation and chemotherapy. 

As clinicians ration penicillin and two more cancer injectable drugs fell into shortage, supply strained recently for nearly a dozen other medications.

Roctavian held promise of treating hemophilia A, but has only been used for one patient since its approval in June 2023, Bloomberg reported Feb. 20. 

RAPT Therapeutics, a San Francisco-based pharmaceutical company, said Feb. 20 that two of its clinical trials are on pause because of one patient's liver failure. 

Mark Cuban Cost Plus Drug Co. now offers two Bayer brand-name medicines: Yaz, an oral contraceptive, and Climara, a menopause treatment. 

The American Medical Association has long been advocating against what it calls "scope creep," or nonphysicians gaining expanded scopes of practice. On Feb. 16, two pharmacist associations fired back. 

In 2023, Vizient secured 37 deals with new and existing customers, including health systems, hospitals and healthcare solutions companies. 

Hospital pharmacy leaders aren't the usual candidate for CEOs and other top positions in health systems, but they might not recognize their existing capabilities. 

While a majority of corporate health insurance plans cover glucagon-like peptide-1 receptor agonist drugs for diabetes, less than a third said they cover the class of drugs for weight loss. However, experts say it's only a matter of time before…

The FDA has approved omalizumab, which goes by the brand name Xolair, as a treatment to reduce the risk of severe allergic reactions for those with food allergies.